Journal
JOURNAL OF VIRUS ERADICATION
Volume 7, Issue 3, Pages -Publisher
MEDISCRIPT LTD
DOI: 10.1016/j.jve.2021.100054
Keywords
SARS-CoV-2; New variants; Spike protein; Receptor binding domain; Human ACE2
Categories
Funding
- Sao Paulo Research Foundation, FAPESP, Brazil [FAPESP 20/12519-4, FAPESP 20/05761-3]
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [20/12519-4] Funding Source: FAPESP
Ask authors/readers for more resources
New variants of SARS-CoV-2 Alpha, Beta, Gamma, and Delta have rapidly spread in various countries, and mutations in the RBD spike protein may lead to increased infectivity compared to the Wuhan 2019 strain.
New variants of SARS-CoV-2 Alpha (B.1.1.7); Beta (B.1.351) Gamma (P.1) and Delta (B.1.617.2) quickly spread in the UK, South Africa, Brazil and India, respectively. To address whether mutations in SARS-CoV-2 RBD spike protein could affect virus infectivity, peptides containing RBD amino acids mutations have been constructed and interacted with human ACE2 by computational methods. Our results suggest that mutations in RBD amino acids K417, E484, L452, T478 and N501 are expressively increasing the affinity of this protein with human angiotensin-converting enzyme 2 (ACE2), consequently, variants Alpha (B.1.1.7), Beta (B1.351), Gamma (P.1) and Delta (B.1.617.2) could be more infective in human cells compared with SARS-CoV-2 isolated in Wuhan2019 and the Gamma and Delta variants could be the most infective among them.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available